MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, BRNS had -$12,110K decrease in cash & cash equivalents over the period. -$10,726K in free cash flow.

Cash Flow Overview

Change in Cash
-$12,110K
Free Cash flow
-$10,726K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-14,571 -40,784
Share based compensation
-415 187
Impairment of long-lived assets
4,667 -
Depreciation and amortization
901 4,035
Non-cash lease expenses
1,449 1,659
Unrealized foreign exchange loss
1,186 -4,869
Change in contingent consideration
17 -339
Non-cash interest expense
13 25
Deferred tax benefit
-71 -47
Profit on sale of property and equipment
68 281
Contract asset (including related parties)
0 -
Prepaid expenses and other current assets
-957 531
Research and development incentives receivable
145 -3,091
Accounts payable
-1,041 -813
Accrued expenses and other current liabilities
-573 -2,767
Deferred income
-156 -342
Operating lease liabilities
-504 -973
Net cash used in operating activities
-10,726 -33,011
Proceeds from sale of property and equipment
451 -
Purchases of property and equipment
0 37
Net cash provided by/(used) in investing activities
451 -37
Proceeds from issue of ordinary shares, net of issuance costs
0 0
Issue of shares from the exercise of stock options
0 2
Net cash provided by financing activities
0 2
Effect of exchange rates on cash, cash equivalents and restricted cash
-1,835 8,430
Net decrease in cash, cash equivalents and restricted cash
-12,110 -24,616
Cash and cash equivalents at beginning of period
112,400 -
Cash and cash equivalents at end of period
75,674 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Barinthus Biotherapeutics plc. (BRNS)

Barinthus Biotherapeutics plc. (BRNS)